8MW-2311 is under clinical development by Mabwell Shanghai Bioscience and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how 8MW-2311’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
8MW-2311 is under development for the treatment of solid tumor, renal cell carcinoma and melanoma. It comprises of pegylated interleukin 12 (IL12) coupled with degradable linker. It acts by targeting interleukin 12 receptor. It is administered through intravenous route.
Mabwell Shanghai Bioscience overview
Mabwell Shanghai Bioscience is a company that is focused on the discovery and industrialization of therapeutic monoclonal antibody, innovative vaccines and long-acting cytokine drugs. The company is headquartered in Shanghai, China.
For a complete picture of 8MW-2311’s drug-specific PTSR and LoA scores, buy the report here.